# Ultrafast, Quantitative Analysis of Buprenorphine, Methadone and Their Metabolites in Human Urine Using Online

SPE/MS/MS Mohamed Youssef, Nikunj Parikh, Vaughn Miller, William LaMarr; Agilent Technologies Inc.,





### Introduction

New high throughput methods are desired to overcome the increasing number of samples requiring analysis in clinical research and forensic toxicology laboratories. Ultrafast SPE/MS/MS systems are capable of analyzing many analytes in biological matrices at a rate of 11-15 seconds per sample. In the present study, we evaluated the capabilities of the Agilent RapidFire High-throughput Mass Spectrometry, an ultrafast SPE/MS/MS system, to quantitatively measure multiple drug panels in human urine; methadone (and its metabolite), and buprenorphine (and its metabolite). The results were then compared to traditional LC/MS/MS analysis.



# **Experimental**

Online SPE methods for each analyte were optimized using a RapidFire High-throughput Mass Spectrometry system coupled to an Agilent 6460 triple quadrupole mass spectrometer. In case of bup/norbup, after the enzymatic hydrolysis, samples were extracted by an offline solid phase extraction procedure using 96 well SPE plates, dried down and reconstituted in 5% methanol in water. Analysis of all samples was performed at a rate of <13 seconds per sample covering the range of 2.5-400 ng/mL. For the MDN/EDDP a simple dilute and shoot method was used over a linear range of 10-5000 ng/mL.

#### **Sample Preparation**

For the bup/norbup panel, after enzymatic hydrolysis, samples were centrifuged at 3,000 rpm for 5 minutes. Then a solid phase extraction protocol was applied on the supernatant using Plexa PCX plates. The eluate from the SPE was dried down under nitrogen, reconstituted with 5% methanol and injected on the RapidFire/MS/MS.

For the MDN/EDDP; 10  $\mu$ L of each urine sample, blank, calibrators and QC were combined with 1 mL of 50% ultrapure water: 50% HPLC grade methanol containing internal standards. The plate was then sealed and shaken for 30 seconds prior to RapidFire/MS/MS analysis.

## **Experimental**

The following MRM transitions were monitored for both panels using Agilent 6460 triple quadrupole mass spectrometer.

Analyte	<b>Q</b> 1	0.3	Fragmentor	CE
Buprenorphine-d4	472.3	59.1	200	62
Buprenorphine Quant	468.3	55.1	200	62
Buprenorphine Qual	468.3	396.2	200	45
NorBuprenorphine-d3	417.3	83.1	188	60
Norbuprenorphine Quant	414.3	83.1	188	60
Norbuprenorphine Qual	414.3	101.1	188	50


Analyte	<b>Q1</b>	0.3	Fragmentor	CE
Methadone-d3	313.2	268.3	85	13
Methadone Quant	310.2	265.0	95	13
Methadone Qual	310.2	105.1	95	29
EDDP-d3	281.2	234.1	100	33
EDDP Quant	278.2	234.1	150	29
EDDP Qual	278.2	249.1	150	25

lonization mode	ESI + Agilent 6460		
Panels	Bup/Norbup	MDN/EDDP	
Drying gas temp.	350 °C	300 °C	
Drying gas flow	10 L/min	10 L/min	
Sheath gas temp.	350 °C	350 °C	
Sheath gas flow	12 L/min	12 L/min	
Nebulizer pressure	35 psi	40 psi	
Nozzle voltage	0 V	0 V	
Capillary voltage	2800 V	2800 V	

RapidFire Method	MDN/EDDP	Bup/Norbup	
Solvent A	H <sub>2</sub> O + 0.1% FA	H <sub>2</sub> O + 5 mM Ammonium Acetate + 0.01%TFA + 0.1% FA	
Solvent B	50% MEOH + 25% IPA + 25% ACN + 0.1% Formic acid		
Solvent C	50% MEOH + 25% IPA + 25% ACN + 0.1% Formic acid		
SPE Cartridge	C18	C18	
RF State 1: Aspirate	600 ms	1000 ms	
RF State 2: Load/Wash	2000 ms	3500 ms	
RF State 3: Extra Wash	0 ms	0 ms	
RF State 4: Elute	4000 ms	6000 ms	
RF State 5: Re-equilibrate	800 ms	2000 ms	

### Results


**Linearity:** The analytes in both panels had excellent linearity within the measured ranges with R<sup>2</sup> values greater than 0.995.



Bup/Norbup standard curves in urine had excellent linearity within the measured range of 2.5-400 ng/mL. The LOQ was determined to be 2.5 ng/mL for both analytes.

MDN/EDDP standard curves in urine had excellent linearity within the measured range of 10-5000 ng/mL. The LOQ was determined to be 5 ng/mL for both analytes.

**Timing and Carryover:** Example of carryover assessment for Bup/Norbup



#### **Precision:**


Inter and intra-day accuracies determined were within 10% and coefficient of variation values were all less than 10% for concentrations within the measured range for both panels.


Norbuprenorphine (ng/mL)	Interday % Accuracy (n=6)	Interday % Precision (n=6)	Intraday % Accuracy (n=6)	Intraday % Precision (n=6)
10 QC	96.3	0.8	98.3	1.1
200 QC	101.6	3.1	107.6	4.7
50 G QC	105.0	2.2	95.2	2.8
330 G QC	108.5	4.9	100.6	4.9
EDDP (ng/mL)	Interday % Accuracy (n=6)	Interday % Precision (n=6)	Intraday % Accuracy (n=6)	Intraday % Precision (n=6)
150 QC	96.1	1.4	99.4	3.3
750 QC	97.8	1.2	100.3	2.3
2000 QC	101.7	1.2	103.5	2.5

#### Results

#### Method Comparison with Blinded Human Samples:

Two sets of 50 and 282 blinded human samples of Bup/Norbup and MDN/EDDP respectively were analyzed by SPE/MS/MS and LC/MS/MS. The results had 100% concordance for positives and negatives and correlated well within the linear range shared between the two methods.





## **Discussion**

- The drug Buprenorphine and its metabolite Norbuprenorphine were accurately and precisely quantified using an Agilent RapidFire High-throughput Mass Spectrometry System. Samples containing analytes were simultaneously analyzed at 12 seconds per sample, using a high-throughput method of quantitation for these analytes that is capable of analyzing more than 270 samples per hour. This SPE/MS/MS methodology provides comparable results to LC/MS/MS, but at >10x the speed and efficiency of typical LC/MS/MS methods.
- The drug methadone and its metabolite EDDP were rapidly, accurately and precisely measured in urine using a simple dilute and shoot procedure and the Agilent RapidFire/MS/MS System. This method covered a broad linear range of 10 to 5000 ng/mL for each analyte. Samples were analyzed at 11 seconds per sample, providing a high-throughput method of analysis for these analytes. This methodology is capable of throughputs greater than 300 samples per hour. The Agilent RapidFire/MS/MS system may be useful for fast and efficient detection of similar small molecule analytes in urine.

**Acknowledgements:** We are grateful to Matthew Woodcock of Dominion Diagnostics for providing blinded human samples and LC/MS/MS data for comparison purposes.